Concerta 45 mg Regimen Using 18 mg + 27 mg Tablets
The current regimen of 45 mg Concerta (18 mg + 27 mg tablets) taken together each morning should be continued if it is providing adequate symptom control throughout the day, as this represents an appropriate total daily dose within the FDA-approved range. However, this dosing approach using two separate tablets is unconventional and should ideally be simplified.
Dosing Considerations
The FDA label for Concerta specifies that it should be taken as a single tablet once daily in the morning 1. The available tablet strengths are 18 mg, 27 mg, 36 mg, and 54 mg. Your patient's 45 mg total dose falls between the standard 36 mg and 54 mg strengths, which creates a dosing challenge.
Recommended Approach
Switch to a single 54 mg tablet once daily if the patient requires coverage beyond what 36 mg provides. The FDA-approved maximum daily dose is 54 mg for children and 72 mg for adolescents and adults 1. Guidelines support titrating in 18 mg increments at weekly intervals 2.
Alternatively, if 36 mg provides nearly adequate control, consider switching to a single 36 mg tablet and reassess symptom coverage throughout the day, particularly during the critical 6-10 hour post-dose period when Concerta reaches peak plasma concentrations 1.
Why This Matters
Concerta's OROS (osmotic release oral system) technology is designed as a single-tablet delivery system that provides:
- 22% immediate-release methylphenidate for rapid onset within 1 hour
- Gradual ascending plasma concentrations over 5-9 hours
- Peak effects between 6-10 hours post-dose
- Duration of action up to 12 hours 2, 1
Taking two separate Concerta tablets simultaneously disrupts this carefully engineered pharmacokinetic profile and may result in unpredictable plasma concentrations and symptom control patterns.
Clinical Monitoring
Assess symptom control at specific time points:
- Morning (1-4 hours post-dose): Early school performance
- Midday (4-8 hours post-dose): Peak effect period
- Afternoon (8-12 hours post-dose): Homework and evening activities
Use standardized rating scales from both parents and teachers to objectively measure response 2. Weight and vital signs should be monitored at each visit during dose adjustments 2.
Common Pitfall
Do not assume that combining tablets to achieve intermediate doses is equivalent to standard single-tablet dosing. The OROS technology in Concerta is tablet-specific, and the pharmacokinetic profile is validated only for intact single tablets 1. Research comparing different methylphenidate formulations demonstrates that delivery mechanisms significantly impact efficacy patterns throughout the day 3, 4, 5.
If 36 mg is insufficient but 54 mg causes side effects, consider switching to a different methylphenidate formulation with a different release profile rather than continuing the two-tablet approach 2.